Treatment of thalamocortical dysrhythmia
A method for treating conditions associated with thalamocortical dysrhythmia. The method includes applying transcranial low voltage electrical stimulation (TLVES) therapy or transcranial magnetic stimulation (TMS) therapy to a patient in need thereof, and administering to the patient a dissociative anesthetic during the TLVES therapy or the TMS therapy. A number of conditions including tinnitus, depression and pain can be treated with TLVES or TMS in combination with the dissociative anesthetic, such as an NMADR inhibitor, including ketamine.
1. A method for treating a condition associated with thalamocortical dysrhythmia, the method comprising in combination:
applying, external to the skull, transcranial magnetic stimulation (TMS) therapy to a patient suffering from a condition associated with thalamocortical dysrhythmia;
administering to the patient intravenously, intramuscularly, orally, intranasally or by inhalation an N-methyl d-aspartate receptor (NMDAR) antagonist during the TMS therapy.
2. The method of claim 1 , wherein the NMDAR antagonist is ketamine.
3. The method of claim 1 , wherein the TMS therapy is further applied at least one of prior to and after the administration of the NMDAR antagonist.
4. The method of claim 1 , further comprising a priming treatment.
5. The method of claim 1 wherein the method is repeated at intervals of 3-7 days.
6. The method of claim 1 , wherein the condition associated with a thalamocortical dysrhythmia is tinnitus.
7. The method of claim 1 , wherein the condition associated with a thalamocortical dysrhythmia is substance abuse.
8. The method of claim 1 , wherein the patient is refractory to pharmacological intervention.
9. A method for treating pain, the method comprising in combination,
applying, external to the skull, transcranial magnetic stimulation (TMS) therapy to an individual having pain;
administering to the individual intravenously, intramuscularly, orally, intranasally or by inhalation an N-methyl d-aspartate receptor (NMDAR) antagonist during the TMS therapy.
10. The method of claim 9 , wherein the TMS therapy is further applied at least one of prior to and after the administration of the NMDAR antagonist.
11. The method of claim 9 , wherein the NMDAR antagonist is ketamine.
12. The method of claim 9 , wherein the NMDAR antagonist is infused over a time period of between about 30 and 60 minutes.
13. The method of claim 9 , further comprising a priming treatment.
14. The method of claim 9 , wherein the method is repeated at intervals of 3-7 days at least five times.
15. The method of claim 9 , wherein the pain is associated with Complex Regional Pain Syndrome or Reflex Sympathetic Dystrophy.
16. The method of claim 9 , wherein the patient is refractory to pharmacological intervention.
17. A method for treating depression, comprising in combination:
applying, external to the skull, transcranial magnetic stimulation (TMS) therapy to a patient suffering from depression;
administering to the patient intravenously, intramuscularly, orally, intranasally or by inhalation an N-methyl d-aspartate receptor (NMDAR) antagonist during the TMS therapy.
18. The method of claim 17 , wherein the TMS therapy is further applied at least one of prior to and after the administration of the NMDAR antagonist.
19. The method of claim 17 , wherein the NMDAR antagonist is infused over a time period of between about 30 and 60 minutes.
20. The method of claim 17 , wherein the NMDAR antagonist is ketamine.
21. The method of claim 17 , further comprising a priming treatment.
22. The method of claim 17 , wherein the method is repeated at intervals of 3-7 days at least five times.
23. The method of claim 17 , wherein the depression is bipolar depression.
24. The method of claim 17 , wherein the patient is refractory to pharmacological intervention.